WO1993004697A1 - Antigenes peptidiques multideterminants qui stimulent la reponse des lymphocytes t auxiliaires au vih chez des sujets humains - Google Patents
Antigenes peptidiques multideterminants qui stimulent la reponse des lymphocytes t auxiliaires au vih chez des sujets humains Download PDFInfo
- Publication number
- WO1993004697A1 WO1993004697A1 PCT/US1992/007422 US9207422W WO9304697A1 WO 1993004697 A1 WO1993004697 A1 WO 1993004697A1 US 9207422 W US9207422 W US 9207422W WO 9304697 A1 WO9304697 A1 WO 9304697A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- peptides
- hiv
- mice
- vaccine
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 150
- 230000004044 response Effects 0.000 title claims abstract description 35
- 108091007433 antigens Proteins 0.000 title claims description 17
- 102000036639 antigens Human genes 0.000 title claims description 17
- 239000000427 antigen Substances 0.000 title claims description 13
- 210000002443 helper t lymphocyte Anatomy 0.000 title abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 95
- 229960005486 vaccine Drugs 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 238000012360 testing method Methods 0.000 claims abstract description 7
- 241000699670 Mus sp. Species 0.000 claims description 38
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 11
- 230000003053 immunization Effects 0.000 claims description 9
- 102000000588 Interleukin-2 Human genes 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 102000054766 genetic haplotypes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 238000002649 immunization Methods 0.000 claims description 7
- 230000004073 interleukin-2 production Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 5
- 230000009696 proliferative response Effects 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 4
- 210000001165 lymph node Anatomy 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 229940023041 peptide vaccine Drugs 0.000 claims description 3
- 102000008072 Lymphokines Human genes 0.000 claims description 2
- 108010074338 Lymphokines Proteins 0.000 claims description 2
- 230000006052 T cell proliferation Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 229940031626 subunit vaccine Drugs 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 238000012412 chemical coupling Methods 0.000 claims 1
- 238000001212 derivatisation Methods 0.000 claims 1
- 238000005516 engineering process Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000010972 statistical evaluation Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 229940125575 vaccine candidate Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 5
- 208000031886 HIV Infections Diseases 0.000 abstract description 4
- 208000037357 HIV infectious disease Diseases 0.000 abstract description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract description 3
- 208000007521 HIV Seropositivity Diseases 0.000 abstract description 2
- 238000002405 diagnostic procedure Methods 0.000 abstract description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 20
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 18
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 18
- 206010022000 influenza Diseases 0.000 description 15
- 230000000638 stimulation Effects 0.000 description 14
- 241000282412 Homo Species 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 8
- 230000005867 T cell response Effects 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 3
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- 101710176384 Peptide 1 Proteins 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 102100021696 Syncytin-1 Human genes 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229960000814 tetanus toxoid Drugs 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940126577 synthetic vaccine Drugs 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 101000800755 Naja oxiana Alpha-elapitoxin-Nno2a Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- -1 sterilants Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003245 working effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the invention is directed to a method for the selection of peptides useful for production of vaccine(s) against HIV infection or as components of a therapeutic mixture or as components of a diagnostic kit for HIV seroconversion.
- the instant application also describes a series of peptides selected by the method.
- SUBSTITUTESHEET virus may contain structures developed by the virus to evade the immune system, such as suppressive epitopes or masking carbohydrates, or structures which elicit deleterious effects such as enhancing antibodies that increase viral infectivity (Takeda, A. et al. Science 242:580-583. (1988); Robinson, W.E.Jr. et al. , Proc. Nati . Acad. Sci. USA 86:4710-4714 (1989); Robinson, W.E.,Jr. et al. ; Proc. Natl. Acad. Sci, USA 87:3185-3189 (1990); Halstead, S.B.
- Purified subunit vaccines have less safety risk, but still may suffer from the other problems of whole virus vaccines. Indeed, because the virus has evolved to evade the immune system, evolution may have favored the development of viral proteins that are hardly optimal as vaccines. Thus, in contrast to enzymes which have been honed by evolution to be the best structures for catalyzing their reactions, viral proteins may leave the scientist with considerable opportunities to improve on nature for the development of better vaccines (Berzofsky, J.A. , J. Clin. Invest. 82:1811-1817 (1988)) . To rationally design highly engineered synthetic or recombinant antiviral vaccines, one needs considerable knowledge about the workings of the immune system, and in particular, about the immune response to structures expressed by the virus.
- CTL cytotoxic T lymphocytes
- helper T cells that would be reguired for either a CTL or an antibody response
- T cells recognize antigens in association with molecules encoded by the major histocompatibility complex (MHC) of the host, and the MHC molecules of any given individual will bind and present only a subset of potential antigenic determinants that could be recognized by the species as a whole (Benacerraf, B. , J. Immunol . 120:1809-1812 (1978); Schwartz, R.H., Annu. Rev. Immunol . 3:237-261 (1985); Berzofsky, J.A. , in "The Antigens", pp. 1 - 146, M. Sela, editor, c. 1987 by Academic Press, New York) .
- MHC major histocompatibility complex
- a vaccine should contain multiple such determinants. Only limited data exist to indicate how many such determinants would have to be included. Although some concern has been raised that the number might be impractical to achieve, some data exist to suggest that as few as four such determinants could elicit responses in 85-90% of outbred humans (Clerici, M. et al. r Nature 339:383-385 (1989)). A few antigenic peptides have been identified that appear to be promiscuous in their recognition in association with many DR molecules (Sinigaglia, F.et al. , natu e 336:778-780 (1.988); Panina-Bordignon, P. et al. , Eur. J. Immunol .
- multideterminant peptides might provide a means to circumvent this problem of MHC restriction in the design of synthetic vaccines.
- the present applicants have, therefore, tested this hypothesis by constructing six synthetic peptides of 20-33 residues each that correspond to the six multideterminant regions of HIV envelope protein localized in the mouse (Hale, P.M. et al., Internat. Immunol . 1:409-415 (1989)), and tested these peptides for their ability to stimulate T-cell responses in mice immunized with recombinant gpl60 and in peripheral blood lymphocytes of humans infected with HIV.
- Figure 2 shows the proliferation response to recombinant gpl60 of T-cells isolated from the lymph nodes of mice immunized with cluster peptides.
- PCLUS2 (324-356) FVTIGKIGNMRQAHCNISRAKWNNTLKQIDSKL (SEQ ID 2)
- PCLUS3 (428-451) KQIINMWQEVGKAMYAPPISGQIR (SEQ ID 3)
- PCLUS4 (483-506) RDNWRSELYKYKWKIEPLGVAPT (SEQ ID 4)
- PCLUS5 (787-820) RIVELLGRRGWEALKYWWNLLQYWSQELKNSAVS
- PCLUS2 (324-356) FVTIGKIGNMRQAHC(NIS)RAKWNNTLKQIDSKL HP-19 FVTIGKIGNMRQAHC HP-20 RAK NNTLKQIDSKL
- BlO.BR/SgSn and B10.D2/nSn strains are obtained from The Jackson Laboratory (Bar Harbor, ME, USA).
- B10.S(9R) and B10A(5R) strains are bred in our colony from breeders obtained from J. Stimpfling and Jackson Laboratories, respectively.
- Recombinant gpl60 is prepared from cells infected with recombinant baculovirus expressing the gene for gpl60 of the HTLV-IIIB isolate of HIV-1 as described (Javaherian, K. et al., Proc. Natl . Acad. Sci . USA 86:6768-6772 (1989)).
- T-cell proliferation assay (Corradin, G. , J. Immunol . 119:1048 (1977)). Mice are immunized subcutaneously in the tail with 20-30 ⁇ g recombinant gpl60 emulsified 1:1 in complete Freund's adjuvant The mice are sacrificed 8-11 days following immunization and their draining inguinal and periaortic lymph nodes are harvested and teased into single cell suspensions in complete T-cell medium (Matis, L.A. et al., J. Immunol . 130:1527-1535 (1983)).
- Each cluster peptide of Table 1 was synthesized and purified as decribed above and tested for the ability to stimulate T-cell proliferative responses of mice of the four MHC types noted that had been immunized with recombinant gpl60.
- BIO congenic mice are used that differed only in their MHC type, but are otherwise genetically identical.
- the four mouse MHC types studied are chosen because they represent four independent MHC haplotypes that each express both an I-A and an I-E molecule, and differ from each other in both of these molecules. Thus the four strains together express eight different murine class II MHC molecules.
- murine I-E molecules like human DR molecules to which they are homologous, all share a conserved alpha chain, but differ in their beta chain, which accounts for all the polymorphism. Responses to most antigens differ among the several I-E and DR alleles, indicating the important role of the beta chain, despite the shared alpha chain.
- Cluster peptide 3 stimulated very strongly in B10.S(9R) , and gave weak but statistically significant responses in the other three strains. The responses were more strongly positive in some experiments for these other strains, but some variability in magnitude of response reduced the geometric mean, although they remained statistically significant.
- These three peptides thus fulfill the predictions of the hypothesis (Hale, P.M. et al., Jnte nat. Immunol . 1:409-415 (1989)) that by making an extended peptide encompassing overlapping antigenic determinants recognized by mice of multiple haplotypes, the resulting construct would be broadly recognized by all or most haplotypes.
- Cluster peptide 2 was strongly positive in only two strains, B10.D2 and BIO.BR, despite the fact that all four strains had recognized at least one site encompassed within this multideterminant region in our earlier study (Hale, P.M. et al., Internat. Immunol. 1:409-415 (1989)).
- cluster peptide 1 was recognized by one strain, BIO.BR, strongly, and by another strain, B10.S(9R) only marginally, despite the fact that all four strains had recognized components of this multideterminant region.
- IL-2 production by human PBL For the assay of antigen-induced IL-2 production by human peripheral blood T cells, PBL from HIV-seropositive asymptomatic blood donors are separated on lymphocyte separation medium (LSM, Organon Teknika Corp, Durham, NC) , washed twice, counted, and resuspended at 3 x 10 6 /ml in RPMI 1640 (Gibco, Grand Island, NY) containing 50 U/ml penicillin and 2 mM glutamine. In triplicate wells in a 96-well flat bottom plate (Costar, Cambridge, MA) , 0.
- LSM lymphocyte separation medium
- RPMI 1640 Gibco, Grand Island, NY
- 1 ml of PBL is added per well and cultured without stimulation or stimulated with: a) influenza A/Bangkok RX73 (final dilution 1: 1000); b) PHA (Gibco) (antigen dilution 1:100); or c) cluster peptides at a final concentration of 2.5 ⁇ M. Pooled AB+ plasma is added to each well (final dilution 1:20). The anti-IL-2 receptor antibody anti-Tac (obtained from Dr. T. A. Waldmann, NCI) is added to each well at the initiation of culture (final concentration 5 ⁇ M) in order to block IL-2 consumption. The supernatants of the cell cultures are harvested 7 d later and frozen at -20 ⁇ C.
- the supernatant IL-2 activity is assessed as the ability to stimulate the proliferation of the IL-2-dependent CTLL cell line as previously described (Clerici, M. et al., J. Clin. Invest. 84:1892-1899 (1989)) .
- peptide envT2 (residues 112-124) contained within cluster peptide 1
- peptide envTl (residues 428-443) contained within cluster peptide 3
- peptide TH4.1 (residues 834-848, also known as HP53) contained within cluster peptide 6 all stimulated responses in 50-67% of HIV-infected human subjects who could still respond to positive-control recall antigens such as influenza A virus (flu) or tetanus toxoid (Clerici, M. et al., Nature 339:383-385 (1989)).
- positive-control recall antigens such as influenza A virus (flu) or tetanus toxoid
- Values shown are stimulation indices for proliferation of an IL-2-dependent CTLL cell line in the presence of a 1:2 dilution of culture supernatant from triplicate cultures of PBL from the indicated donor with a 2.5 ⁇ M concentration of the indicated peptide, as described above. All of the seropositive donors and controls studied were responsive to the positive control recall protein antigen flu. For a value to be considered positive, it had to simultaneously meet two criteria: The replicates had to be statistically significantly different from the control replicates for that donor by Student's t test (p ⁇ 0.05), and the stimulation index had to be greater than twice the medium control. Six cases marked NS were stimulation indices > 2.0 which were not counted as positives because the replicates were not statistically significant. In several cases with SI ⁇ 2.0, the replicates were significantly different from background, but these were not considered positive because of the low stimulation index. The requirement for both criteria is thus more conservative than using either alone.
- Cluster peptides 1 and 3 were most broadly recognized, giving responses in 64% and 73% of the donors.
- Cluster peptides 2, 5, and 6 were close seconds, positive in 58, 59, and 58% of the donors, respectively.
- the least broadly recognized was cluster peptide 4, but even this stimulated 52% of the donors.
- none or only one of the control seronegative donors responded to any of the peptides except cluster peptide 2, which stimulated 2 of the 15 control donors (13 %) . Thus, none of the peptides was nonspecifically mitogenic.
- the peptides in the mixture may compete with each other for binding to some MHC molecules, given the small sample sizes in the two groups studied, there is probably not a statistically significant difference between the fraction responding to at least one peptide in the first group and the fraction responding to the mixture in the second. In either case, we conclude that a sizable majority of people are capable of making T cell responses to these peptides.
- the peptides identified by the two screening techniques above are to be useful components of a vaccine, it is important that they not only be recognized by T-cells immune to the HIV envelope protein gpl60, but also that they be immunogenic to elicit T cells in vivo that can respond to gpl60.
- the immunizations cannot be performed yet in the clinically relevant species, (uninfected) humans, but it is desirable to be sure that for the strains of mice shown above to have T cells responsive to these peptides, the mice can be immunized in vivo with the peptides and elicit T cells that respond to intact gpl60 in vitro.
- mice of the strain responding best to that peptide based on the data in Fig. 1.
- Mice of the four strains shown are immunized subcutaneously in the tail with 8-10 nmoles of the indicated cluster peptide in a 1:1 emulsion with CFA, final volume per mouse 50 ⁇ l except for cluster peptide 2 which was in 75 ⁇ l. Twelve days later, the draining lymph nodes are harvested from 2 mice of each group (strain and peptide combination) and assayed as described above. Results are shown as stimulation indices, the ratio of experimental cpm over cpm from stimulation with medium alone, which ranged from 3000-7000 cpm for the different groups.
- BIO.BR mice immunized with cluster peptide 1, cluster peptide 5, or cluster peptide 6 all produced T cells that could be stimulated by recombinant gpl60 in vitro (Fig. 2, panel A) .
- T cells from BIO.BR mice immunized with only complete Freunds adjuvant did not respond significantly to the gpieo in vitro (Fig. 2, panel A). Therefore, the in vitro response was a result of immunization with the peptides.
- T cells from BlO.S(9R) mice immunized with either cluster peptide 3 or cluster peptide 4 responded to recombinant gpl60 in vitro, whereas similar mice immunized with adjuvant alone made a weak (mitogenic) response at only the highest concentration (Fig. 2, panel B) .
- BIO.A(5R) mice immunized with cluster peptide 6 and B10.D2 mice immunized with cluster peptide 2 produced T cells responsive to gpl60 in vitro (Fig. 2, panels C and D) .
- Example 2 Use of cluster peptides in a diagnostic assay for HIV- 1 infection of patients
- the cluster peptides described in Table 1 above may be utilized for the diagnosis of HIV-1 positive seroconversion in patients.
- the detection of HIV-1 gpl60 specific T cell responses to these peptides can be accomplished by standard techniques of T-ell proliferation and production of IL-2 or other lymphokines as described above in Example 1, items 4 and 5, applied to humans as described in Clerici et al.. Nature, Vol. 339, pp. 383-385 (1989).
- the diagnostic test can be of a cytotoxicity format as described for the peptide env-I ⁇ in Berzofsky, et al., U.S. patent application Serial Number 07/148,692.
- This format has the advantage of detecting infected individuals that are not yet producing antibodies to HIV.
- Example 3 Chemical modification of the cluster peptides to enhance their pharmacologic characteristics
- Small peptides circulating in the blood are subject to degradation by proteolytic action and clearing by the kidneys. Yet, a number of naturally occurring peptides are found in the circulation, for example the enkephalins. These small peptides are often found to be modified by amidation of the carboxy-terminus (Kitamura, K. et al. , Biochem. Biophys. Res. Comm. 169:1164-1171 (1990) ; Dickson, C. J. and Yamada, T. , J. Biol. Chem. 266:334-338 (1991)).
- the peptides of the instant invention could also be coupled to, or co-synthesized with, peptides that bind to or induce production of neutralizing ' antibodies to HIV or cytotoxic T-cells specific for HIV.
- the peptides of the instant invention serve as HIV I-specific carriers in such constructs, which advantageously induces a memory in T-cells which would cause a memory helper T-cell response on exposure to HIV, in contrast to the use of HIV-unrelated carriers which would not produce such a memory response on exposure to the virus.
- Useful HIV-I specific carriers are, for example; as described in Good, M.F. et al., Science, Vol. 235, pp. 1059-1062 (1987); U.S. Patent No. 4,886,782 to Good et al.; and Palker, T. J. et al., J. of Immunology, Vol. 142, pp. 3612-3619 (1989), which are hereby incorporated by reference.
- a pharmaceutical composition including a vaccine in accordance with the present invention comprises an effective antigenic or therapeutic amount of at least one of the cluster peptides and a pharaceutically acceptable carrier such as physiological saline, non- toxic, sterile buffer and the like.
- a pharaceutically acceptable carrier such as physiological saline, non- toxic, sterile buffer and the like.
- additives such as preservatives, sterilants, adjuvants and the like, well known to one of ordinary skill in the art, could also be included in the pharmaceutical composition to maintain or increase the efficacy of the preparation.
- peptides of the instant invention can also be administered as a vaccine in a fashion similar to that for the administration to primates of a synthetic peptide vaccine against hepatitus B as described by Itoh (Itoh, Y. et al., Proc. Natl. Acad. Sci. USA 83:9174-9178 (1986)).
- An alternative method for the preparation of vaccines involves the use of Protein A coated microbeads that bind immune complexes of an antibody and the immunizing antigen on their outer surface described for eample in Platt, et al., U.S. patent number 4,493,825, hereby incorporated by reference.
- the cluster peptides of the invention could be coupled to, or conjugated with, peptides that bind to or induce.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU25693/92A AU665023B2 (en) | 1991-08-29 | 1992-08-31 | Multideterminant peptide antigens that stimulate helper T lymphocyte response to HIV in a range of human subjects |
CA002114849A CA2114849C (fr) | 1991-08-29 | 1992-08-31 | Antigenes peptidiques multideterminants qui stimulent la reponse des lymphocytes t auxiliaires contre le hiv chez une gamme de sujets humains |
DK92919588T DK0601108T3 (da) | 1991-08-29 | 1992-08-31 | Multideterminante peptidantigener, som stimulerer T-hjælpelymfocytrespons til HIV hos en gruppe mennesker |
JP5505385A JPH07501516A (ja) | 1991-08-29 | 1992-08-31 | ヒトの被験者におけるhivに反応するヘルパーtリンパ球を刺激する多重決定基ペプチド抗原 |
EP92919588A EP0601108B1 (fr) | 1991-08-29 | 1992-08-31 | Antigenes peptidiques multideterminants qui stimulent la reponse des lymphocytes t auxiliaires au vih chez des sujets humains |
DE69230106T DE69230106T2 (de) | 1991-08-29 | 1992-08-31 | Peptid-antigene bestehend aus multi-determinanten, die die t-helfer lymphozyten-antwort gegen hiv in einem weiten bereich von betroffenen menschen stimulieren |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75199891A | 1991-08-29 | 1991-08-29 | |
US751,998 | 1991-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993004697A1 true WO1993004697A1 (fr) | 1993-03-18 |
Family
ID=25024412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/007422 WO1993004697A1 (fr) | 1991-08-29 | 1992-08-31 | Antigenes peptidiques multideterminants qui stimulent la reponse des lymphocytes t auxiliaires au vih chez des sujets humains |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0601108B1 (fr) |
JP (1) | JPH07501516A (fr) |
AT (1) | ATE185275T1 (fr) |
AU (1) | AU665023B2 (fr) |
CA (1) | CA2114849C (fr) |
DE (1) | DE69230106T2 (fr) |
DK (1) | DK0601108T3 (fr) |
ES (1) | ES2257733T3 (fr) |
WO (1) | WO1993004697A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994026785A1 (fr) * | 1993-05-14 | 1994-11-24 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERIVCES | Produits genetiques de peptides synthetiques composites declenchant des anticorps et des lymphocytes t cytotoxiques de neutralisation contre vih |
WO1995003067A1 (fr) * | 1993-07-21 | 1995-02-02 | Khavinson Vladimir Khatskelevi | Agents pharmaceutiques a activite immunomodulatrice |
US5603933A (en) * | 1993-08-31 | 1997-02-18 | Board Of Regents, The University Of Texas | CD4 peptides for binding to viral envelope proteins |
US5972339A (en) * | 1997-11-13 | 1999-10-26 | The General Hospital Corporation | Method of eliciting anti-HIV-1 helper T cell responses |
US6210873B1 (en) | 1987-08-28 | 2001-04-03 | Board Of Regents, The University Of Texas System | Methods and compositions for the priming of specific cytotoxic T-lymphocyte response |
US6265539B1 (en) | 1987-08-28 | 2001-07-24 | The University Of Texas System The Board Of Regents | Prophylaxis and therapy of acquired immunodeficiency syndrome |
US6982086B2 (en) | 2000-02-04 | 2006-01-03 | Duke University | Human immunodeficiency virus immunogenic composition |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110349627B (zh) * | 2019-06-27 | 2021-08-27 | 杭州纽安津生物科技有限公司 | 多肽疫苗序列的设计方法及其自动化设计产品 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4943628A (en) * | 1988-06-13 | 1990-07-24 | Ortho Pharmaceutical Corporation | HIV peptide-inducted T cell stimulation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3787002T2 (de) * | 1986-12-30 | 1993-11-25 | Us Health | Synthetische Peptide, die zelluläre Immunität gegen den AIDS-Virus und dessen Proteine erzeugen. |
US5030449A (en) * | 1988-07-21 | 1991-07-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Synthetic vaccine against AIDS virus |
ATE151638T1 (de) * | 1987-02-20 | 1997-05-15 | Genentech Inc | Verfahren und zubereitungen für die verwendung von hiv-env-polypeptiden und antikörpern |
US5128319A (en) * | 1987-08-28 | 1992-07-07 | Board Of Regents, The University Of Texas System | Prophylaxis and therapy of acquired immunodeficiency syndrome |
AU2914889A (en) * | 1987-08-28 | 1989-04-17 | Board Of Regents, The University Of Texas System | Prophylaxis and therapy of acquired immunodeficiency syndrome |
ATE128716T1 (de) * | 1987-11-24 | 1995-10-15 | Abbott Lab | Hiv-peptide und methoden für den nachweis von hiv. |
CA1341285C (fr) * | 1988-02-12 | 2001-08-14 | Chang Yi Wang | Peptides synthetiques servant a la detection d'anticorps de la proteine de surface gp120 du virus hiv, destines au diagnostic du sida, ainsi que d'etats pre-sidatiques, ou aux fins de vaccins |
CA2003383A1 (fr) * | 1988-11-23 | 1990-05-23 | Sushil G. Devare | Antigenes de hiv recombinants derives d'adn synthetique |
WO1991015512A2 (fr) * | 1990-04-03 | 1991-10-17 | Genentech, Inc. | Polypeptides d'enveloppe du vih |
ES2194836T3 (es) * | 1990-09-27 | 2003-12-01 | Tripep Ab | Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana. |
-
1992
- 1992-08-31 ES ES92919588T patent/ES2257733T3/es not_active Expired - Lifetime
- 1992-08-31 DE DE69230106T patent/DE69230106T2/de not_active Expired - Lifetime
- 1992-08-31 WO PCT/US1992/007422 patent/WO1993004697A1/fr active IP Right Grant
- 1992-08-31 CA CA002114849A patent/CA2114849C/fr not_active Expired - Lifetime
- 1992-08-31 AT AT92919588T patent/ATE185275T1/de active
- 1992-08-31 JP JP5505385A patent/JPH07501516A/ja active Pending
- 1992-08-31 AU AU25693/92A patent/AU665023B2/en not_active Ceased
- 1992-08-31 DK DK92919588T patent/DK0601108T3/da active
- 1992-08-31 EP EP92919588A patent/EP0601108B1/fr not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4943628A (en) * | 1988-06-13 | 1990-07-24 | Ortho Pharmaceutical Corporation | HIV peptide-inducted T cell stimulation |
Non-Patent Citations (3)
Title |
---|
Nature, Volume 334, issued 25 August 1988, BERZOFSKY et al., "Antigenic Peptides Recognized by T Lymphocytes from AIDS Viral Envelope-Immune Humans", pages 706-708, see entire article. * |
Nature, Volume 339, issued 01 June 1989, CLERICI et al., "Interleukin-2 Production Used to Detect Antigenic Peptide Recognition by T-Helper Lymphocytes from Asymptomatic HIV-Seropositive Individuals", pages 383-385, see entire article. * |
Proceedings National Academy of Sciences, Volume 84, issued June 1987, CEASE et al., "Helper T-Cell Antigenic Site Identification in the Acquired Immunodeficiency Syndrome gp120 Envelope Protein and Induction of Immunity in Mice to the Native Protein Using a 16-Residue Synthetic Peptide", pages 4249-4253, see * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7094405B1 (en) | 1986-12-30 | 2006-08-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Peptides which elicit a high neutralizing antibody titer, cytotoxic T lymphocyte response and T helper cell response in a broad range of MHC type recipients |
US6210873B1 (en) | 1987-08-28 | 2001-04-03 | Board Of Regents, The University Of Texas System | Methods and compositions for the priming of specific cytotoxic T-lymphocyte response |
US6265539B1 (en) | 1987-08-28 | 2001-07-24 | The University Of Texas System The Board Of Regents | Prophylaxis and therapy of acquired immunodeficiency syndrome |
US6214347B1 (en) | 1988-01-26 | 2001-04-10 | The United States Of America As Represented By The Department Of Health And Human Services | Multideterminant peptides that elicit helper T-lymphocyte, cytotoxic T lymphocyte and neutralizing antibody responses against HIV-1 |
US5932218A (en) * | 1988-01-26 | 1999-08-03 | The United States Of America As Represented By The Department Of Health & Human Services | Multideterminant peptides eliciting helper T-lymphocyte, cytotoxic T-lymphocyte, and neutralizing antibody responses against HIV-1 |
US6294322B1 (en) | 1988-01-26 | 2001-09-25 | The United States Of America As Represented By The Department Of Health And Human Services | Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1 |
WO1994026785A1 (fr) * | 1993-05-14 | 1994-11-24 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERIVCES | Produits genetiques de peptides synthetiques composites declenchant des anticorps et des lymphocytes t cytotoxiques de neutralisation contre vih |
WO1995003067A1 (fr) * | 1993-07-21 | 1995-02-02 | Khavinson Vladimir Khatskelevi | Agents pharmaceutiques a activite immunomodulatrice |
US5603933A (en) * | 1993-08-31 | 1997-02-18 | Board Of Regents, The University Of Texas | CD4 peptides for binding to viral envelope proteins |
US5972339A (en) * | 1997-11-13 | 1999-10-26 | The General Hospital Corporation | Method of eliciting anti-HIV-1 helper T cell responses |
US6982086B2 (en) | 2000-02-04 | 2006-01-03 | Duke University | Human immunodeficiency virus immunogenic composition |
US7052699B2 (en) | 2000-02-04 | 2006-05-30 | Duke University | Immunogenic composition |
US7078039B2 (en) | 2000-02-04 | 2006-07-18 | Duke University | Immunogenic composition |
Also Published As
Publication number | Publication date |
---|---|
EP0601108B1 (fr) | 1999-10-06 |
DK0601108T3 (da) | 2000-04-17 |
EP0601108A1 (fr) | 1994-06-15 |
ES2257733T3 (es) | 2006-08-01 |
DE69230106D1 (de) | 1999-11-11 |
AU2569392A (en) | 1993-04-05 |
AU665023B2 (en) | 1995-12-14 |
CA2114849A1 (fr) | 1993-03-18 |
CA2114849C (fr) | 2007-04-24 |
DE69230106T2 (de) | 2000-03-30 |
ATE185275T1 (de) | 1999-10-15 |
JPH07501516A (ja) | 1995-02-16 |
EP0601108A4 (en) | 1997-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5939074A (en) | Multideterminant peptide antigens | |
Berzofsky et al. | Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. | |
US6265539B1 (en) | Prophylaxis and therapy of acquired immunodeficiency syndrome | |
EP0273716B1 (fr) | Peptides synthétiques induisant l'immunité cellulaire contre le virus du SIDA et ses protéines | |
US8236324B2 (en) | Nucleotide sequences of HIV-1 group (or subgroup) O retroviral antigens | |
US5030449A (en) | Synthetic vaccine against AIDS virus | |
CA2162880C (fr) | Peptides synthetiques mixtes induisant l'action d'anticorps neutralisants et de lymphocytes t cytotoxiques contre le vih | |
US20060240030A1 (en) | Anti-hiv immunogenic formulation and process for preparation thereof | |
AU621097B2 (en) | A synthetic antigen evoking anti-hiv response | |
EP0554389B1 (fr) | Clones moleculaires de vih-1 et utilisation de ces derniers | |
US5935579A (en) | AIDS therapy and vaccine | |
AU665023B2 (en) | Multideterminant peptide antigens that stimulate helper T lymphocyte response to HIV in a range of human subjects | |
NZ513388A (en) | Treatment using multi-subtype FIV vaccines | |
Valentine et al. | A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with⩾ 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137) | |
BAHRAOUI et al. | Immunogenicity of the human immunodeficiency virus (HIV) recombinant nef gene product. Mapping of T-cell and B-cell epitopes in immunized chimpanzees | |
Berzofsky | Mechanisms of T cell recognition with application to vaccine design | |
Kurata et al. | Immunodominant sites of human T cell lymphotropic virus type 1 envelope protein for murine helper T cells. | |
Lee et al. | A single point mutation in HIV-1 V3 loop alters the immunogenic properties of rgp120 | |
EP1476182B1 (fr) | Procede de preparation des formulations immunogeniques d'epitopes peptidiques variables | |
McBride et al. | Comparison of serum antibody reactivities to a conformational and to linear antigenic sites in the external envelope glycoprotein of simian immunodeficiency virus (SIVmac) induced by infection and vaccination | |
US5882853A (en) | Method of evaluating HTLV-I-specific T cell responses | |
Kelker et al. | Immunogenic and antigenic properties of an HIV-1 gp120-derived multiple chain peptide. | |
Eriksson et al. | Systematic identification of T-cell activating epitopes on the human immunodeficiency virus type 1 envelope glycoprotein gp120 in primates immunized with synthetic peptides | |
World Health Organization | The use of synthetic antigens for diagnosis of infectious diseases: report of a WHO scientific group [meeting held in Geneva from 30 November to 4 December 1987] | |
Ahlers | Developing synthetic peptide vaccines for HIV-1: the design and characterization of multideterminant T helper-CTL/neutralizing antibody vaccine constructs and the use of cytokines for steering immune responses toward desired functional types |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2114849 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992919588 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992919588 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992919588 Country of ref document: EP |